Montmorillonite as an Anti-Tuberculosis Rifampicin Drug Carrier: DFT and Experimental Study

被引:3
|
作者
Scholtzova, Eva [1 ]
Jankovic, Lubos [1 ]
Tunega, Daniel [2 ]
机构
[1] Slovak Acad Sci, Inst Inorgan Chem, Dubravska Cesta 9, Bratislava 84536, Slovakia
[2] Univ Nat Resources & Life Sci Vienna, Inst Soil Res, Dept Forest & Soil Sci, Peter Jordan Str 82, A-1190 Vienna, Austria
关键词
DFT-D3; Drug carrier; Hydrogen bonds; Molecular dynamics; Montmorillonite; Rifampicin; TEMPERATURE MOLECULAR-DYNAMICS; DENSITY-FUNCTIONAL THEORY; STRUCTURAL-PROPERTIES; CATIONS; TETRABUTYLPHOSPHONIUM; FORMULATION; ADSORPTION; SIMULATION; STABILITY; RELEASE;
D O I
10.1007/s42860-023-00245-5
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
A hybrid of montmorillonite (Mnt) and rifampicin (RIF) was synthesized and the structure and stability of the drug carrier system clarified. Density functional theory calculations involving dispersion corrections (DFT-D3) were performed to characterize interactions acting in the interlayer space of montmorillonite intercalated with rifampicin. The structure and stability of the RIF-Mnt intercalated complex were determined. Calculations revealed the deformation of the molecular structure of rifampicin after intercalation into the Mnt interlayer space due to the clay environment. The ansa chain of RIF was bent in the interlayer space compared with the structure of the RIF molecule in the monocrystal. RIF was keyed into the Mnt surface by means of numerous hydrogen bonds of weak to moderate strength. The calculated vibrational spectrum from ab initio molecular dynamics (AIMD) was in good agreement with the FTIR measured spectra and helped to analyze the overlapped vibrational bands. Based on analysis of structural stability, theoretical calculations revealed that Mnt is a suitable drug carrier for delayed release of the RIF drug. Batch adsorption experiments showed the large adsorption capacity of montmorillonite for RIF.
引用
收藏
页码:229 / 241
页数:13
相关论文
共 50 条
  • [11] Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand
    Maze, M. J.
    Paynter, J.
    Chiu, W.
    Hu, R.
    Nisbet, M.
    Lewis, C.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (07) : 955 - 960
  • [12] Voltammetric and spectroscopic studies on the interaction of anti-cancer herbal drug rutin with an anti-tuberculosis agent rifampicin
    Ender Biçer
    Serkan Özdemir
    Russian Journal of Electrochemistry, 2010, 46 : 896 - 903
  • [13] Voltammetric and spectroscopic studies on the interaction of anti-cancer herbal drug rutin with an anti-tuberculosis agent rifampicin
    Bicer, Ender
    Ozdemir, Serkan
    RUSSIAN JOURNAL OF ELECTROCHEMISTRY, 2010, 46 (08) : 896 - 903
  • [14] Anti-tuberculosis drug resistance in Portugal
    Antunes, ML
    Aleixo-Dias, J
    Antunes, AF
    Pereira, MF
    Raymundo, E
    Rodrigues, MF
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2000, 4 (03) : 223 - 231
  • [15] PYRAZINAMIDE IS A MAJOR ANTI-TUBERCULOSIS DRUG
    PRETET, S
    LIARD, R
    PERDRIZET, S
    LANCET, 1982, 1 (8268): : 399 - 399
  • [16] NEUROTOXICITY OF ETHAMBUTOL ANTI-TUBERCULOSIS DRUG
    SCHMIDT, I
    ANATOMICAL RECORD, 1964, 148 (02): : 333 - &
  • [17] Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model
    Disratthakit, Areeya
    Doi, Norio
    Takenaga, Mitsuko
    Ohta, Yuki
    JOURNAL OF MICROENCAPSULATION, 2010, 27 (04) : 365 - 371
  • [18] Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles
    Moretton, Marcela A.
    Glisoni, Romina J.
    Chiappetta, Diego A.
    Sosnik, Alejandro
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2010, 79 (02) : 467 - 479
  • [19] Rifamycins: do not throw the baby out with the bathwater. Is rifampicin still an effective anti-tuberculosis drug?
    Brucoli, Federico
    D McHugh, Timothy
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (24) : 2129 - 2131
  • [20] Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs
    Kurbatova, E. V.
    Cavanaugh, J. S.
    Shah, N. S.
    Wright, A.
    Kim, H.
    Metchock, B.
    Van Deun, A.
    Barrera, L.
    Boulahbal, F.
    Richter, E.
    Martin-Casabona, N.
    Arias, F.
    Zemanova, I.
    Drobniewski, F.
    Santos Silva, A.
    Coulter, C.
    Lumb, R.
    Cegielski, J. P.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (03) : 355 - 357